Hepatic ratio of phosphatidylcholine to phosphatidylethanolamine predicts survival after partial hepatectomy in mice

Hepatology

Volumn 55, Issue 4, 2012, Pages 1094-1102

  Ling, Ji ^a   Chaba, Todd ^a   Zhu, Lin Fu ^a   Jacobs, René L ^a   Vance, Dennis E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD68 ANTIGEN; CHOLINE; GLUCOSE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; INFLAMMATION; LIPID DIET; LIVER HISTOLOGY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; STEATOSIS; SURVIVAL;

ANIMALS; CHOLINE; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; DIETARY FATS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; HEPATECTOMY; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; PHOSPHATIDYLETHANOLAMINES; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE;

EID: 84859165083     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24782     Document Type: Article

References (41)

1. Matteoni C, Younossi ZM, McCullough A. Nonalcoholic fatty liver disease: a spectrum of clinical pathological severity. Gastroenterology 1999; 116: 1413-1419.
2. Day CP, James OFW. Hepatic steatosis: innocent bystander or guilty party? HEPATOLOGY 1998; 27: 1463-1466.
3. Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006; 3: 321-331.
4. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. HEPATOLOGY 2007; 46: 1081-1090.
5. Vance DE. Phospholipid biosynthesis in eukaryotes. In: Vance DE, Vance JE, eds. Biochemistry of Lipids, Lipoproteins and Membranes. 5th ed. New York: Elsevier; 2008: 213-244.
6. DeLong CJ, Shen YJ, Thomas MJ, Cui Z. Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway. J Biol Chem 1999; 274: 29683-29688.
7. Tang W, Keesler GA, Tabas I. The structure of the gene for murine CTP:phosphocholine cytidylyltransferase, Ctpct. J Biol Chem 1997; 272: 13146-13151.
8. Karim M, Jackson P, Jackowski S. Gene structure, expression and identification of a new CTP:phosphocholine cytidylyltransferase [beta] isoform. Biochim Biophys Acta 2003; 1633: 1-12.
9. Noga AA, Vance DE. A gender-specific role for phosphatidylethanolamine N-methyltransferase-derived phosphatidylcholine in the regulation of plasma high density and very low density lipoproteins in mice. J Biol Chem 2003; 278: 21851-21859.
10. Jacobs RL, Devlin C, Tabas I, Vance DE. Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase alpha in mice decreases plasma high density and very low density lipoproteins. J Biol Chem 2004; 279: 47402-47410.
11. Jacobs RL, Zhao Y, Koonen DPY, Sletten T, Su B, Lingrell S, et al. Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity. J Biol Chem 2010; 285: 22403-22413.
12. Song J, da Costa KA, Fischer LM, Kohlmeier M, Kwock L, Wang S, et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J 2005; 19: 1266-1271.
13. Veteläinen R, van Vliet A, Gouma D, van Gulik T. Steatosis as a risk factor in liver surgery. Ann Surg 2007 245: 20-30.
14. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transplant 2006; 12: 523-534.
15. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253.
16. Higgins HM, Andersen RM. Experimental pathology of liver: restoration of liver of the white rat following partial surgical removal. Arch Pathol 1931; 12: 186-202.
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
18. Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. HEPATOLOGY 2009; 49: 809-820.
19. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
20. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
21. Rouser G, Siakotos AN, Fleishcher S. Quantitative analysis of phospholipids by thin-layer chromatography and phosphorus analysis of spots. Lipids 1966: 85-86.
22. Snyder F, Stephens N. A simplified spectrophotometric determination of ester groups in lipids. Biochim Biophys Acta 1959: 244-245.
23. Waite KA, Cabilio NR, Vance DE. Choline deficiency-induced liver damage is reversible in Pemt-/- mice. J Nutr 2002; 132: 68-71.
24. Jezek P. Possible physiological roles of mitochondrial uncoupling proteins-UCPn. Int J Biochem Cell Biol 2002; 34: 1190-1206.
25. Ockner RK. Metabolism and gene expression in liver regeneration. In: Integration of Metabolism, Energetics, and Signal Transduction. 1st ed. New York: Springer; 2004: 177-190.
26. Ridgway ND, Yao Z, Vance DE. Phosphatidylethanolamine levels and regulation of phosphatidylethanolamine N-methyltransferase. J Biol Chem 1989; 264: 1203-1207.
27. Walkey CJ, Donohue LR, Bronson R, Agellon LB, Vance DE. Disruption of the murine gene encoding phosphatidylethanolamine N-methyltransferase. Proc Natl Acad Sci U S A 1997; 94: 12880-12885.
28. Haines D, Rose C. Impaired labelling of liver phosphatidylethanolamine from ethanolamine-14C in choline deficiency. Can J Biochem 1970; 48: 885-892.
29. Kumar VV. Complementary molecular shapes and additivity of the packing parameter of lipids. Proc Natl Acad Sci U S A 1991; 88: 444-448.
30. Phillips R, Ursell T, Wiggins P, Sens P. Emerging roles for lipids in shaping membrane-protein function. Nature 2009; 459: 379-385.
31. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
32. Serviddio G, Bellanti F, Tamborra R, Rollo T, Romano AD, Giudetti AM, et al. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Eur J Clin Invest 2008; 38: 245-252.
33. Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, Tamagawa Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2007; 31: S61-S66.
34. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-5700.
35. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004; 4: 686-693.
36. He S, Atkinson C, Evans Z, Ellett JD, Southwood M, Elvington A, et al. A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol 2009; 183: 4764-4772.
37. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
38. Wunderlich FT, Ströhle P, Könner AC, Gruber S, Tovar S, Brönneke HS, et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 2010; 12: 237-249.
39. Buchman A, Ament M, Sohel M, Dubin M, Jenden D, Roch M, et al. Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial. JPEN J Parenter Enteral Nutr 2001; 25: 260-268.
40. Best CH, Hartroft WS, Lucas CC, Ridout JH. Liver damage produced by feeding alcohol or sugar and its prevention by choline. Br Med J 1949; 2: 1001-1006.
41. Detopoulou P, Panagiotakos DB, Antonopoulou S, Pitsavos C, Stefanadis C. Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: the ATTICA study. Am J Clin Nutr 2008; 87: 424-430.